Search

Your search keyword '"Multidrug-resistant Enterobacteriaceae"' showing total 2 results
Start Over Descriptor "Multidrug-resistant Enterobacteriaceae" Publisher elsevier
2 results on '"Multidrug-resistant Enterobacteriaceae"'

1. In vitro activity of tigecycline against multidrug-resistant Enterobacteriaceae isolates from skin and soft tissue infections

Author

Ashoka Mahapatra and Srujana Mohanty

Subjects
Experimental Research, Klebsiella pneumoniae, Tigecycline, medicine.disease_cause, Microbiology, 03 medical and health sciences, Minimum inhibitory concentration, 0302 clinical medicine, medicine, Escherichia coli, biology, business.industry, Soft tissue infection, Multidrug-resistant Enterobacteriaceae, General Medicine, biology.organism_classification, Enterobacteriaceae, In vitro, Multiple drug resistance, 030220 oncology & carcinogenesis, 030211 gastroenterology & hepatology, Surgery, business, Bacteria, medicine.drug
Abstract

Background Tigecycline, a new agent against multidrug-resistant (MDR) bacteria, is especially licensed for use in complicated skin and soft tissue and intra-abdominal infections. We aimed to study the recent in vitro activity of tigecycline against MDR Enterobacteriaceae skin and soft tissue isolates. Methods Consecutive isolates (56 Escherichia coli, 48 Klebsiella pneumoniae) were subjected to tigecycline susceptibility testing by Ezy MIC test and interpreted as per European Committee on Antimicrobial Susceptibility Testing. Results The minimum inhibitory concentrations (MICs) of tigecycline ranged from 0.016 to 48 μg/mL, with MIC50 0.19 μg/mL and MIC90 1.0 μg/mL respectively. Seven (6.7%) isolates were resistant to tigecycline, all K. pneumoniae. Conclusion Tigecycline remains a viable therapeutic option against MDR isolates, with excellent in vitro activity against E. coli and promising activity against K. pneumoniae. However, the limited availability of alternate therapeutic armamentarium necessitates its use with extreme judiciousness along with continuous monitoring for the emergence and spread of resistance., Highlights • Tigecycline has excellent in vitro activity against MDR E. coli. • Tigecycline has comparatively lower activity against MDR K. pneumoniae. • Tigecycline remains a viable therapeutic option against MDR E. coli isolates. • Limited availability of alternate therapy necessitates cautious use of tigecycline.

Published
2021

2. Assessment of five screening strategies for optimal detection of carriers of third-generation cephalosporin-resistant Enterobacteriaceae in intensive care units using daily sampling.

Author

Grohs P, Podglajen I, Guerot E, Bellenfant F, Caumont-Prim A, Kac G, Tillecovidin B, Carbonnelle E, Chatellier G, Meyer G, Fagon JY, and Gutmann L

Subjects
Adult, Aged, Aged, 80 and over, Bacteriological Techniques, Carrier State microbiology, Critical Care methods, Enterobacteriaceae drug effects, Enterobacteriaceae Infections microbiology, Female, Humans, Male, Mass Screening methods, Microbial Sensitivity Tests, Middle Aged, Rectum microbiology, Retrospective Studies, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization, beta-Lactam Resistance, Anti-Bacterial Agents pharmacology, Carrier State diagnosis, Cephalosporins pharmacology, Enterobacteriaceae isolation & purification, Enterobacteriaceae Infections diagnosis, Infection Control methods, Intensive Care Units
Abstract

There is no consensus on optimal screening procedures for multidrug-resistant Enterobacteriaceae (MDRE) in intensive care units (ICUs). Therefore, we assessed five strategies for the detection of extended-spectrum beta-lactamase (ESBL) and high-level expressed AmpC cephalosporinase (HL-CASE) producers. During a 3-month period, a rectal screening swab sample was collected daily from every ICU patient, from the first 24 h to the last day of ICU stay. Samples were plated on MDRE-selective media. Bacteria were identified using MALDI-TOF mass spectrometry and antibiograms were performed using disk diffusion. MDREs were isolated from 682/2348 (29.0%) screening samples collected from 93/269 (34.6%) patients. Incidences of patients with ESBL and HL-CASE producers were 17.8 and 19.3 per 100 admissions, respectively. In 48/93 patients, MDRE carriage was intermittent. Compared with systematic screening at admission, systematic screening at discharge did not significantly increase the rate of MDRE detection among the 93 patients (62% vs. 70%). In contrast, screening at admission and discharge, screening at admission and weekly thereafter, and screening at admission and weekly thereafter and at discharge significantly increased MDRE detection (77%, p 0.02; 76%, p 0.01; 86%, p<0.001, respectively). The difference in MDRE detection between these strategies relies essentially on the levels of detection of patients with HL-CASE producers. The most reasonable strategy would be to collect two samples, one at admission and one at discharge, which would detect 87.5% of the ESBL strains, 67.3% of the HL-CASE strains and 77.4% of all MDRE strains. This study should facilitate decision-making concerning the most suitable screening policy for MDRE detection in a given ICU setting., (© 2014 The Authors Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectious Diseases.)

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results